Floatz logo

gpc3-car-t cells

Myxoid/Round Cell Liposarcoma

Sotio Biotech Inc.Cell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myxoid/Round Cell Liposarcoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Sotio Biotech Inc.
Phase 1/2CCC
Cyclophosphamide
Sotio Biotech Inc.
Phase 1/2CCC
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
USWM CT, LLC
Phase 1CC
Ny-Eso-1 Tcr Redirected Autologous T Cell Product
University of Pennsylvania
Phase 1CC

Same molecule, other indications

gpc3-car-t cells is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
squamous cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →